Support a People’s Vaccine

We, the undersigned, join Oxfam, UNAIDs, the World Health Organization, hundreds of world leaders and Nobel Laureates calling for a People’s Vaccine. We believe that all COVID-19 tests, treatments, and vaccines developed with public money should be accessible to everyone, affordably priced, and free at the point-of-delivery. A coordinated global response is the only way to stop a global pandemic.

COVID INFECTIONS
32,925,668 confirmed
COVID DEATHS
995,414 deaths
Public funds spent on pharmaceutical research
Over $11 billion

Pharmaceutical corporation controlled monopolies and exclusive licenses will not solve this problem.

Access to vaccines and treatments as global public goods are in the interests of all humanity.

Oxfam International

We call for universities, organizations, and companies receiving public funds for COVID research to sign the Open COVID Pledge, a legal commitment to open licensing the intellectual property needed for the cure.

For information on calls to Free the Vaccine for COVID-19:

Your signature will help demonstrate support for change at your organization and/or university – whether you are faculty, alumni, student, staff, or a member of the surrounding community.

I want my institution to sign on to the Open Covid Pledge:






More information for institutions

What is the Open COVID Pledge?

The Open Covid Pledge offers legal tools for institutions to publicly commit to make their COVID-19 related intellectual property (IP) freely available. You implement the Pledge through a license that includes terms and conditions for how the IP is made available. You have the option of adopting one of three template Open COVID Licenses (the simplest and easiest way) or you can adopt your own license so long as it carries out the intent of the Pledge.

Instead of granting a typical exclusive license to one company to produce the drug, by making the Open COVID Pledge you allow anyone to access the patented invention “solely for the purpose of diagnosing, preventing, containing, and treating COVID-19.”

It doesn’t guarantee that multiple pharmaceutical companies, start-ups, or governments would immediately start producing a technology. But it does offer that option. And we know that there is no way that one company will be able to produce enough diagnostics, treatments, and vaccines for 7.8 billion people – so this kind of license just makes sense.

“Billions of people today await a vaccine that is our best hope of ending this pandemic. As the countries of Africa, we are resolute that the COVID-19 vaccine must be patent-free, rapidly made and distributed, and free for all. All the science must be shared between governments. Nobody should be pushed to the back of the vaccine queue because of where they live or what they earn.”

Cyril Ramaphosa
President of South Africa

Okay, it sounds good in theory, but I’m worried that this isn’t a feasible way to develop new medicines…

Forms of open access licensing have been used to develop new medicines and health technologies – often at a fraction of the cost of the traditional model. Here are a few examples, but you can also check out Universities Allied for Essential Medicines’ RE:Route Mapping Tool, which provides 81 alternative R&D models, 49 of which were in use by 2015.

  • The Drugs for Neglected Diseases Initiative, which develops lifesaving medicines for people with neglected diseases around the world, has an access policy for products they develop. It is guided by principles and objectives including “facilitate equitable access to the new treatments developed by DNDi” and “enter into agreements with manufacturers to secure long term treatment and/or API production…at lowest Cost of Goods Sold and price, of acceptable quality, and with IP enabling global access”.
  • The Medicines Patent Pool signed a licensing agreement with Johns Hopkins University to facilitate the clinical development of sutezolid, a promising tuberculosis treatment. JHU granted the Medicines Patent Pool an exclusive, royalty-free license covering all countries that currently have patents issued or pending for a sutezolid combination therapy.
  • M4K Pharma, a non-profit pharmaceutical company, shares all research openly and files no patents on its results. They are currently working on a treatment for Diffuse intrinsic pontine glioma (DIPG), a rare and fatal children’s brain cancer for which the only life-extending treatment is radiation therapy. Nearly every child diagnosed with the disease dies within two years.
  • The Structural Genomics Consortium has developed a number of chemical probes for epigenetics — valued reagents in fundamental and applied biological research — since 2008.

How much public money has my institution’s COVID-19 project received?

Find out here! We created an online mapping tool that tracks public investment in global COVID-19 research and development. This tracking tool aims to map where public funding and taxpayer supported R&D initiatives are taking place, in order to better support policy making that uses every means necessary to ensure that those specific diagnostics, vaccines, and therapies are available to all.

Learn more at publicmeds4covid.org

Why should my institution sign on?

  • Fulfill your institution’s mission, vision, and/or goals
  • Attract and retain students and faculty seeking institutions with coherence in statements and actions.
  • Contribute real meaning and impact: your discovery can help most people around the world
  • Sharing your scientific discoveries with other researchers will prevent more infection and disease
  • Practice your commitment to the principles of the scientific process and to the scientific community
  • Ensure fair and equitable access for publicly funded research
  • Reduce healthcare inequities for our friends and family around the world

What’s the point of developing a life-saving innovation if those who need it the most can’t access it?

I represent an institution ready to sign on. Let’s do this thing.